Showing results (21-30 of 89) with videos related to

Sort By:
Pageof 9
Oncogene|July 12, 2005
Betulinic acid as new activator of NF-kappaB: molecular mechanisms and implications for cancer therapyHubert Kasperczyk, Katia La Ferla-Brühl, Mike Andrew Westhoff, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|March 29, 2017
Cancer stem cells: The potential role of autophagy, proteolysis, and cathepsins in glioblastoma stem cellsJoachim Bischof, Mike-Andrew Westhoff, Johanna Elisabeth Wagner, et al.
Plos One|January 7, 2014
Sequential dosing in chemosensitization: targeting the PI3K/Akt/mTOR pathway in neuroblastomaMike-Andrew Westhoff, Najmeh Faham, Daniela Marx, et al.
Biomedicines|September 12, 2019
Temozolomide and Other Alkylating Agents in Glioblastoma TherapyHannah Strobel, Tim Baisch, Rahel Fitzel, et al.
Experimental Hematology|November 12, 2013
Transitory dasatinib-resistant states in KIT(mut) t(8;21) acute myeloid leukemia cells correlate with altered KIT expressionMarkus D Herrmann, Jochen K Lennerz, Lars Bullinger, et al.
Oncotarget|April 19, 2017
Mitochondrial matrix chaperone and c-myc inhibition causes enhanced lethality in glioblastomaChiaki Tsuge Ishida, Chang Shu, Marc-Eric Halatsch, et al.
Scientific Reports|October 20, 2018
Dual Inhibition of Bcl-2/Bcl-xL and XPO1 is synthetically lethal in glioblastoma model systemsEnyuan Shang, Yiru Zhang, Chang Shu, et al.
Cancers|December 23, 2023
Inhibition of Survivin Homodimerization Decreases Neuroblastoma Cell GrowthCarmen Dorneburg, Celimene Galiger, Giovanna L Stadler, et al.
Oncotarget|October 17, 2015
TIC10/ONC201 synergizes with Bcl-2/Bcl-xL inhibition in glioblastoma by suppression of Mcl-1 and its binding partners in vitro and in vivoGeorg Karpel-Massler, Maïmouna Bâ, Chang Shu, et al.
Oncotarget|May 14, 2016
Metabolic reprogramming of glioblastoma cells by L-asparaginase sensitizes for apoptosis in vitro and in vivoGeorg Karpel-Massler, Doruntina Ramani, Chang Shu, et al.
Pageof 9